On Jul. 13, 2020, Lonza and Junshi Biosciences announced that the first healthy volunteer had been dosed in a Phase I clinical study of JS016 at Huashan Hospital affiliated to Fudan University in China in Jun.. JS016 was the first SARS-CoV-2 neutralizing antibody that had entered clinical trials in China and was produced using Lonzaﾒs GS Xceed Expression System. This follows on from a successful launch of the first PD-1-targeting antibody using GS Xceed last year.